Vudalimab

DB18833Investigational

Vudalimab is under investigation in clinical trial NCT05005728 (Xmab®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-resistant Prostate Cancer).

Mechanism: Pharmacologically active on Cytotoxic T-lymphocyte protein 4 and Programmed cell death protein 1
Curator reviewed
Also known as: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717 · Anti-pd1/ctla4 bispecific antibody xmab20717 · Immunoglobulin half-ig g1-kappa/scfv-h-ch2-ch3, anti-(homo sapiens ctla4 (cytotoxic t-lymphocyte-associated protein 4, cd152)) and anti-(homo sapienspdcd1 (programmed cell death 1, pd-1, pd1, cd279)), monoclonal antibody, bispecific · Pd-1 x ctla-4 dual checkpoint inhibitor xmab20717
Code names: ANTI-PD-1/ANTI-CTLA-4 XMAB20717 · XMAB-20717

Resolves to

Compound

UNII4I9I5X3Z6NCAS2329669-72-7

Targets

P16410CTLA4Q15116PDCD1

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vudalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account